NEW YORK (GenomeWeb News) – Vermillion today announced a $16.4 million offering of common stock.

The Austin, Texas-based diagnostics firm is offering 8,350,000 shares of common stock at $1.96 per share. The company has also granted the underwriters a 30-day option to purchase up to an additional 1,252,500 shares to cover over-allotments. Net proceeds after deducting expenses are expected to be roughly $15.2 million.

The offering is expected to close on or about July 17.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.